Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCL

Tycel J. Phillips, MD
Published: Thursday, Jan 10, 2019



Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, Phillips presented data on the combination of acalabrutinib and BR in patients with treatment-naïve or relapsed/refractory MCL. High efficacy rates were observed, especially in treatment-naïve patients. Moreover, over 70% of patients experienced a complete response rate.

The combination was deemed safe and effective. Adverse-events seemed to be evenly dispersed between the treatment-naïve and relapsed/refractory patients. Traditionally, bendamustine is a safe backbone upon which to test novel therapies, says Phillips. Although a high rate of infection has been noted in other studies with bendamustine, this was not the case with the addition of acalabrutinib, he explains. Further analysis into T cell subsets could provide additional insight into the potential risk for infection.
SELECTED
LANGUAGE


Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, Phillips presented data on the combination of acalabrutinib and BR in patients with treatment-naïve or relapsed/refractory MCL. High efficacy rates were observed, especially in treatment-naïve patients. Moreover, over 70% of patients experienced a complete response rate.

The combination was deemed safe and effective. Adverse-events seemed to be evenly dispersed between the treatment-naïve and relapsed/refractory patients. Traditionally, bendamustine is a safe backbone upon which to test novel therapies, says Phillips. Although a high rate of infection has been noted in other studies with bendamustine, this was not the case with the addition of acalabrutinib, he explains. Further analysis into T cell subsets could provide additional insight into the potential risk for infection.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x